These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28555258)

  • 1. Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.
    Battella S; Cox MC; La Scaleia R; Di Napoli A; Di Landro F; Porzia A; Franchitti L; Mainiero F; Ruco L; Monarca B; Santoni A; Palmieri G
    Cancer Immunol Immunother; 2017 Oct; 66(10):1295-1306. PubMed ID: 28555258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.
    Cox MC; Battella S; La Scaleia R; Pelliccia S; Di Napoli A; Porzia A; Cecere F; Alma E; Zingoni A; Mainiero F; Ruco L; Monarca B; Santoni A; Palmieri G
    Oncoimmunology; 2015 Mar; 4(3):e990773. PubMed ID: 25949906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Shin HJ; Kim DY; Chung J; Shin KH; Lee H
    Acta Haematol; 2021; 144(4):427-437. PubMed ID: 33271543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
    Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
    Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma.
    Coleman M; Lammers PE; Ciceri F; Jacobs IA
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):175-81. PubMed ID: 26906106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood lymphocyte subsets of newly diagnosed DLBCL patients and their dynamic changes with rituximab based immunochemotherapy.
    Yang Z; Yu W; Wang S; Zhou X; Liu S; Ma S
    Leuk Lymphoma; 2019 Dec; 60(12):2909-2916. PubMed ID: 31120360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy.
    Hou H; Luo Y; Tang G; Zhang B; Ouyang R; Wang T; Huang M; Wu S; Li D; Wang F
    Cancer Cell Int; 2021 May; 21(1):282. PubMed ID: 34044841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of circulating neutrophils and lymphocyte subsets in newly diagnosed patients with diffuse large B-cell lymphoma.
    Yang Z; Yu W
    Clin Exp Med; 2023 Jul; 23(3):815-822. PubMed ID: 35939174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and function of CD4
    Cha Z; Gu H; Zang Y; Wang Z; Li J; Huang W; Qin A; Zhu L; Tu X; Cheng N; Song H; Qian B
    Int Immunopharmacol; 2018 Aug; 61():132-139. PubMed ID: 29870918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma.
    Vaughan J; Wiggill T; Lawrie D; Machaba M; Patel M
    PLoS One; 2023; 18(1):e0280044. PubMed ID: 36630466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Liu G; Luan J; Li Q
    DNA Cell Biol; 2016 Dec; 35(12):845-852. PubMed ID: 27704876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
    Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
    Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Kusano Y; Yokoyama M; Terui Y; Nishimura N; Mishima Y; Ueda K; Tsuyama N; Yamauchi H; Takahashi A; Inoue N; Takeuchi K; Hatake K
    Blood Cancer J; 2017 Apr; 7(4):e558. PubMed ID: 28430176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
    Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models.
    Stirm K; Leary P; Wüst D; Stark D; Joller N; Karakus U; Boyman O; Tzankov A; Müller A
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
    Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.
    Plonquet A; Haioun C; Jais JP; Debard AL; Salles G; Bene MC; Feugier P; Rabian C; Casasnovas O; Labalette M; Kuhlein E; Farcet JP; Emile JF; Gisselbrecht C; Delfau-Larue MH;
    Ann Oncol; 2007 Jul; 18(7):1209-15. PubMed ID: 17496307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.